Date of Presentation

5-5-2022 12:00 AM

College

School of Osteopathic Medicine

Poster Abstract

Bladder cancer represents the 6th most common for men and is classified into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). NMIBC (T1, Ta, Tis), accounting for approximately 75% of new bladder cancer diagnoses, is limited to the mucosa, submucosa, and lamina propria. Studies have approximated the rate of recurrence in NMIBC between 50 - 70%, which sometimes progresses to muscle invasive disease. Management of NMIBC ranges from surveillance, intravesical chemotherapy to radical cystectomy (RC) and is dependent upon the TNM staging and grading of the tumor. Clinically, staging is determined via imaging, physical exam, and histology on transurethral resection of bladder tumor (TURBT), while pathologic grading is determined via radical cystectomy and pelvic lymph node dissection (PLND).

PLND has been shown to have a therapeutic benefit in localized bladder cancer when done in conjunction with RC, in addition to diagnostic and therapeutic elements. While the relationship between PLND and MIBC has been studied extensively, the role of lymph node (LN) dissection during RC for NMIBC remains unclear, with few studies and conflicting results. Furthermore, although lymph node metastasis has been found to occur in up to 16.2% of NMIBC patients, its reported that nearly half have insufficient PLND during RC and 16.6% have no PLND done at all. The aim of this data analysis is to determine the predictive factors and outcomes for LN positive patients undergoing PLND with RC in NMIBC.

Keywords

Neoplasms, Urologic Neoplasms, Lymph Node Excision, Cystectomy

Disciplines

Male Urogenital Diseases | Medicine and Health Sciences | Neoplasms | Oncology | Surgical Procedures, Operative | Urogenital System | Urology

Document Type

Poster

Share

COinS
 
May 5th, 12:00 AM

Factors and Outcomes Contributing to Pelvic Lymph Node Dissection in Non-Muscle Invasive Bladder Cancer

Bladder cancer represents the 6th most common for men and is classified into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). NMIBC (T1, Ta, Tis), accounting for approximately 75% of new bladder cancer diagnoses, is limited to the mucosa, submucosa, and lamina propria. Studies have approximated the rate of recurrence in NMIBC between 50 - 70%, which sometimes progresses to muscle invasive disease. Management of NMIBC ranges from surveillance, intravesical chemotherapy to radical cystectomy (RC) and is dependent upon the TNM staging and grading of the tumor. Clinically, staging is determined via imaging, physical exam, and histology on transurethral resection of bladder tumor (TURBT), while pathologic grading is determined via radical cystectomy and pelvic lymph node dissection (PLND).

PLND has been shown to have a therapeutic benefit in localized bladder cancer when done in conjunction with RC, in addition to diagnostic and therapeutic elements. While the relationship between PLND and MIBC has been studied extensively, the role of lymph node (LN) dissection during RC for NMIBC remains unclear, with few studies and conflicting results. Furthermore, although lymph node metastasis has been found to occur in up to 16.2% of NMIBC patients, its reported that nearly half have insufficient PLND during RC and 16.6% have no PLND done at all. The aim of this data analysis is to determine the predictive factors and outcomes for LN positive patients undergoing PLND with RC in NMIBC.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.